Can we use old NAFLD data under the new MASLD definition?

We read with interest the article by Rinella et al. published in the Journal of Hepatology.1 After four rounds of Delphi survey, the term metabolic dysfunction-associated steatotic liver disease (MASLD) was chosen to replace non-alcoholic fatty liver disease (NAFLD). This exercise was triggered by the proposal in 2020 to rename NAFLD as metabolic-associated fatty liver disease (MAFLD).2 Both MASLD and MAFLD involve a change in not only the nomenclature but also the definition.3 Apart from allowing MASLD/MAFLD to co-exist with other chronic liver diseases, the diagnosis involves the presence of metabolic risk factors (MASLD: at least 1 of 5 metabolic factors; MAFLD: presence of type 2 diabetes, overweight/obesity, or at least 2 other metabolic factors).